Equifax
EFX
$173.20
+1.87%
Equifax is a leading global data, analytics, and technology company, operating as one of the three major credit bureaus in the United States alongside Experian and TransUnion. Its core business involves providing consumer credit reports, risk assessment, and identity verification services critical to lenders' decisions, while also deriving significant revenue from workforce solutions like income verification and HR services. The current investor narrative is dominated by the company's ongoing recovery and strategic repositioning following a significant data breach, with recent focus on its ability to leverage data analytics and AI to drive growth amidst a competitive landscape where rivals are also advancing their own technological capabilities. Recent price weakness and analyst activity suggest the market is weighing the company's resilience against economic headwinds and its execution on digital transformation initiatives.…
EFX
Equifax
$173.20
Related headlines
Investment Opinion: Should I buy EFX Today?
Rating & Thesis: Hold. EFX is a fundamentally sound company caught in a severe sentiment downdraft, presenting a conflicted picture where attractive forward valuation and strong cash flow are offset by technical weakness and operational inconsistency. The analyst consensus leans bullish, but the stock's performance suggests the market is demanding clearer evidence of execution before rewarding it.
Supporting Evidence: The primary valuation metric, the forward P/E of 16.88x, is reasonable for a company with 9.24% revenue growth and a 10.87% net margin, suggesting the market has priced in significant pessimism. The company's robust TTM free cash flow of $1.13 billion provides a solid financial foundation. However, these positives are counterbalanced by the stock's 33.29% annual decline, a high beta of 1.559 indicating elevated volatility, and the alarming quarterly gross margin collapse which clouds the earnings outlook.
Risks & Conditions: The two biggest risks are the persistence of gross margin volatility and a failure to re-accelerate revenue growth above the high-single-digit range. This Hold rating would upgrade to a Buy if the forward P/E compressed further towards 14x without a deterioration in earnings estimates, or if the company demonstrates a return to stable, historical gross margin levels above 40% for two consecutive quarters. It would downgrade to a Sell if revenue growth decelerates below 5% or if free cash flow generation meaningfully weakens. Based on the current data, the stock appears fairly valued to slightly undervalued on a forward basis, but the operational inconsistencies prevent a clear undervaluation call.
Sign up to view all
EFX 12-Month Price Forecast
EFX presents a classic 'show me' story. The valuation has corrected to a reasonable forward multiple, and the company's cash-generating ability is undeniable. However, the extreme quarterly margin volatility and sustained technical downtrend cannot be ignored; they signal underlying operational or competitive stress. The neutral stance reflects the high probability of the base case—a period of stabilization without a major catalyst. Confidence is medium due to the lack of clarity on margins. The stance would upgrade to bullish on evidence of sustained margin recovery for two quarters, or downgrade to bearish on a confirmed breakdown below the $166 support level on high volume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Equifax's 12-month outlook, with a consensus price target around $225.16 and implied upside of +30.0% versus the current price.
Average Target
$225.16
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$139 - $225
Analyst target range
The stock is covered by 13 analysts, indicating substantial institutional interest. The consensus sentiment leans bullish, as evidenced by recent institutional ratings which include actions like 'Overweight' from Morgan Stanley and 'Buy' from Stifel and Needham, with no recent downgrades noted among the provided data. While the exact average target price and Buy/Hold/Sell distribution are not provided in the analyst data block, the presence of multiple 'Outperform' and 'Buy' ratings from major firms in February 2026 suggests analyst confidence is being tested but not broken by the recent price decline. The target price range and implied upside cannot be calculated from the given data, but the wide dispersion in recent quarterly valuation multiples (e.g., PS ratio ranging from 4.4 to over 28 historically) signals high uncertainty among investors regarding the appropriate valuation framework, with the low target likely pricing in sustained competitive and macroeconomic pressures, while the high target would require successful execution on margin expansion and growth initiatives.
Bulls vs Bears: EFX Investment Factors
The evidence currently tilts bearish, driven by the stock's severe technical breakdown, high volatility, and inconsistent quarterly margins that undermine confidence in near-term execution. However, strong underlying free cash flow, a bullish analyst consensus, and a reasonable forward valuation provide a foundation for a potential recovery. The single most important tension in the investment debate is the resolution of gross margin volatility: if Q4's 10.96% margin was an anomaly and the company can stabilize margins near historical levels, the bull case based on earnings power becomes credible. If the margin compression persists, it will validate bearish concerns about deteriorating fundamentals and justify further multiple compression.
Bullish
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with $1.13 billion TTM and $340.8 million in Q4 2025. This provides significant liquidity to service its debt, fund strategic investments, and return capital to shareholders, underpinning financial resilience.
- Analyst Consensus Remains Bullish: Despite the stock's decline, analyst sentiment leans bullish with 13 covering firms and recent 'Overweight' and 'Buy' ratings from major institutions like Morgan Stanley and Stifel. This suggests professional confidence in the company's long-term recovery and digital transformation.
- Attractive Forward Valuation: The stock trades at a forward P/E of 16.88x, a significant discount to its trailing P/E of 40.48x. This gap implies the market expects a substantial earnings recovery, with consensus EPS estimates at $16.97, offering potential for multiple expansion if met.
- Positive Revenue Growth Trajectory: Q4 2025 revenue grew 9.24% year-over-year to $1.55 billion. While growth has plateaued sequentially, the underlying trend remains positive, indicating the core business is still expanding despite economic and competitive pressures.
Bearish
- Severe Technical Downtrend: The stock is in a pronounced downtrend, down 33.29% over the past year and trading just 4.7% above its 52-week low of $166.02. It has severely underperformed the S&P 500 by over 62 percentage points in the last year, indicating deep investor pessimism.
- High Volatility and Beta: With a beta of 1.559, EFX is approximately 56% more volatile than the broader market. This amplifies downside risk in weak markets and increases the stock's sensitivity to negative news, contributing to its sharp recent declines.
- Significant Gross Margin Volatility: Quarterly gross margins are highly inconsistent, collapsing from 57.07% in Q3 2025 to 10.96% in Q4 2025. This extreme volatility raises questions about cost structure stability, pricing power, and the sustainability of profitability.
- Elevated Trailing Valuation: The trailing P/E of 40.48x remains elevated despite the price decline, sitting above historical lows near 27x. This suggests the valuation has compressed but may not yet be at a deep discount, leaving room for further multiple contraction if earnings disappoint.
EFX Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -33.29% and a 6-month decline of -17.65%. Currently trading at $173.85, the price sits just 4.7% above its 52-week low of $166.02, positioning it in the extreme lower end of its annual range and signaling deep investor pessimism and potential oversold conditions, though it also represents a significant value trap risk if fundamentals deteriorate further. Recent momentum shows continued weakness, with a 1-month decline of -3.23% and a 3-month drop of -13.68%, both figures starkly underperforming the S&P 500's gains of 9.98% and 4.14% over the same periods, indicating severe negative relative strength and a lack of any near-term bullish catalyst to arrest the slide. Key technical support is firmly established at the 52-week low of $166.02, while resistance lies far above at the 52-week high of $281.03; a breakdown below support could trigger another leg down, while the stock's high beta of 1.559 confirms it is approximately 56% more volatile than the broader market, amplifying both downside risk and potential for sharp rebounds on any positive news.
Beta
1.35
1.35x market volatility
Max Drawdown
-39.6%
Largest decline past year
52-Week Range
$166-$281
Price range past year
Annual Return
-33.9%
Cumulative gain past year
| Period | EFX Return | S&P 500 |
|---|---|---|
| 1m | -4.9% | +11.4% |
| 3m | -9.3% | +8.3% |
| 6m | -16.6% | +9.4% |
| 1y | -33.9% | +31.3% |
| ytd | -19.1% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EFX Fundamental Analysis
Revenue growth remains positive but has shown signs of deceleration; the most recent Q4 2025 revenue was $1.55 billion, representing a year-over-year growth of 9.24%, yet this follows a sequential decline from Q3's $1.54 billion and Q2's $1.54 billion, indicating a potential plateau in top-line expansion. The company is profitable with a Q4 net income of $175.7 million, but profitability metrics are mixed, as the quarterly gross margin of 10.96% is a sharp contraction from the 57.07% reported in Q3 2025, while the trailing twelve-month net margin stands at 10.87%, suggesting underlying operational efficiency despite quarterly volatility in cost structures. The balance sheet carries moderate financial risk with a debt-to-equity ratio of 1.11, but it is supported by strong cash generation, evidenced by free cash flow of $340.8 million in Q4 and a robust TTM free cash flow of $1.13 billion, providing ample liquidity to service debt, fund investments, and return capital to shareholders, as indicated by a current ratio of 0.60 which, while low, is mitigated by the strong cash flow profile.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.10%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EFX Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 40.48x, which is significantly higher than its forward PE of 16.88x; this wide gap implies the market expects a substantial recovery in earnings over the next twelve months, likely pricing in the analyst consensus EPS estimate of $16.97. Compared to its own historical range, the current trailing PE of 40.48x is below the multi-quarter highs seen above 64x in 2024 but remains elevated relative to lows near 27x in 2021-2022, suggesting the valuation has compressed from optimistic levels but may not yet be at a deep historical discount, reflecting ongoing earnings uncertainty. Industry comparison data is not available in the provided dataset, preventing a direct sector premium/discount analysis; however, the high single-digit revenue growth and double-digit net margin profile would typically command a premium, though the current multiple compression likely reflects heightened risk perceptions.
PE
40.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: EFX faces significant financial risks from its inconsistent profitability profile, most notably the extreme quarterly gross margin volatility which collapsed from 57.07% to 10.96% between Q3 and Q4 2025. This makes forecasting earnings exceptionally difficult. While the debt-to-equity ratio of 1.11 is manageable, the low current ratio of 0.60 indicates a reliance on strong and consistent free cash flow generation ($1.13B TTM) to service obligations, creating vulnerability if cash flow weakens. Revenue growth, while positive at 9.24% YoY in Q4, has plateaued sequentially, raising concerns about the company's ability to re-accelerate top-line expansion in a competitive market.
Market & Competitive Risks: The stock's high beta of 1.559 makes it highly sensitive to broader market swings, amplifying downside risk during periods of risk aversion. Valuation compression is a key risk, as the trailing P/E of 40.48x, though down from highs, remains elevated and could contract further if growth decelerates. Competitive disruption is a tangible threat, as highlighted by recent news noting that established rivals are building their own AI tools, potentially eroding EFX's technological edge in data analytics. Furthermore, as a credit bureau, the company's revenue is inherently cyclical and sensitive to interest rates and lending activity, adding macroeconomic sensitivity.
Worst-Case Scenario: The worst-case scenario involves a combination of sustained gross margin pressure, a significant slowdown in lending activity due to a recession, and competitive inroads from rivals leveraging AI. This could lead to consecutive earnings misses, triggering analyst downgrades and a loss of investor confidence. In this adverse scenario, the stock could retest and break below its 52-week low of $166.02, potentially falling towards levels implied by a deeper historical discount on earnings. From the current price of $173.85, this represents a realistic downside of approximately -20% to -25%, with the potential for greater losses if sentiment turns severely negative, mirroring the stock's maximum drawdown of -39.58%.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Extreme quarterly gross margin volatility (from 57% to 11%), which undermines earnings predictability and suggests potential cost or pricing issues. 2) Market Risk: High beta of 1.559 means EFX will fall more than the market in a downturn, as evidenced by its 62-percentage-point underperformance vs. the S&P 500 over the past year. 3) Competitive Risk: Rivals like Experian and TransUnion are advancing their own AI and analytics capabilities, threatening EFX's growth initiatives. 4) Financial Risk: A low current ratio of 0.60 indicates reliance on consistent cash flow to meet short-term obligations.
The 12-month outlook for EFX is framed by three scenarios. The Base Case (55% probability) sees the stock trading between $190 and $220 as the company stabilizes operations with modest growth, meeting its $16.97 EPS estimate. The Bull Case (25% probability) projects a rally to $240-$260 on successful margin recovery and growth re-acceleration. The Bear Case (20% probability) warns of a decline to $160-$175 if operational issues persist and earnings disappoint. The base case is most likely, hinging on the critical assumption that the company can demonstrate more consistent quarterly profitability in upcoming reports.
EFX sends mixed valuation signals. On a trailing basis, with a P/E of 40.48x, it appears expensive. However, the forward P/E of 16.88x, based on analyst EPS estimates of $16.97, suggests the market expects a sharp earnings recovery and the stock may be fairly valued or slightly undervalued. The price-to-sales ratio of 4.4x is also reasonable for a profitable data company. Compared to its own history, the valuation has compressed from much higher levels. The current multiple implies the market is paying a fair price for anticipated future earnings, but is demanding proof that those earnings will materialize given recent margin instability.
EFX is a speculative buy for investors with a higher risk tolerance and a medium-term horizon. The forward P/E of 16.88x is attractive relative to its earnings growth potential, and the strong free cash flow provides a safety net. However, it is not a good buy for risk-averse investors, as the stock is in a severe downtrend, exhibits high volatility (beta 1.56), and faces unresolved operational issues, notably wild swings in gross margin. A purchase should be predicated on the belief that the company can stabilize its profitability and that the current price already reflects significant bad news.
EFX is unsuitable for short-term trading due to its high volatility (beta 1.56) and lack of a clear near-term catalyst to reverse its downtrend. It is better suited for a long-term investment horizon of 2-3 years, allowing time for the company's strategic digital transformation to bear fruit, for margins to potentially normalize, and for the valuation discount to be recognized. The stock's low dividend yield of 0.87% indicates it is not an income play. Patient investors buying at current levels are making a contrarian bet on a fundamental recovery, which requires a longer time frame to play out.